Antinociceptive Effect of Gosha-jinki-gan, a Kampo Medicine, in Streptozotocin-Induced Diabetic Mice

The Japanese Journal of Pharmacology

Yasuhiro Komatsu¹  Junzo Kamei²  Yasuyuki Suzuki¹  Kazuhiro Goto¹  Atsushi Ishige¹ 

[1] Kampo and Pharmacognosy Laboratories, Tsumura & Co.;Department of Pathophysiology & Therapeutics, Faculty of Pharmaceutical Sciences, Hoshi University,

关键词: Gosha-jinki-gan;    Antinociception;    Diabetes;    Processed Aconiti tuber;    Dynorphin;   

DOI  :  10.1254/jjp.79.169

学科分类：药理学

来源: Nihon Yakuri Gakkai Henshuubu / Japanese Pharmacological Society

【 摘 要 】

References(27)Cited-By(37)We evaluated the antinociceptive effect of Gosha-jinki-gan, a Kampo medicine including processed Aconiti tuber, and its mechanism in streptozotocin-induced diabetic mice. Gosha-jinki-gan (0.1 - 1.0 g/kg, p.o.) showed a more potent antinociceptive effect in diabetic mice than in non-diabetic mice. The antinociceptive effect of Gosha-jinki-gan (0.3 g/kg, p.o.) in diabetic mice was inhibited by administration of either anti-dynorphin antiserum (5 μg, i.t.) or nor-binaltorphimine (10 mg/kg, s.c.), a κ-opioid antagonist. The antinociceptive activity of Gosha-jinki-gan (0.3, 1.0 g/kg, p.o.) was decreased by excluding processed Aconiti tuber. Furthermore, the antinociceptive effect of processed Aconiti tuber (0.03, 0.1 g/kg, p.o.) was also shown to be enhanced in diabetic mice. These results suggest that the increased antinociceptive effect of Gosha-jinki-gan in diabetic mice is partly derived from the action of processed Aconiti tuber and that it is based on stimulation of spinal κ-opioid receptors via dynorphin release. Gosha-jinki-gan was considered useful for treating painful diabetic neuropathy.

【 授权许可】

Unknown